Insider Monkey·2026-03-15 01:11Core Viewpoint - The article discusses the 12 most profitable blue-chip stocks to invest in currently, emphasizing the importance of diversification and identifying opportunities amidst market volatility [1][2][3]. Market Trends and Investment Strategy - Stephen Parker from JPMorgan Private Bank highlights that geopolitical events, such as the Iran war, can cause short-term market disruptions, particularly in energy markets, but typically do not have long-lasting effects [1][2]. - He advises clients to maintain a diversified and disciplined investment approach, seek opportunities during volatility, and start building a shopping list for potential investments [2][3]. Stock Selection Methodology - The selection of the 12 blue-chip stocks was based on stock screeners and holdings of blue-chip ETFs, focusing on those with the highest trailing twelve months (TTM) net income and net income margins [5]. - The list prioritizes stocks with the highest number of hedge fund holders as of Q3 2025, utilizing data from Insider Monkey's database [5][6]. Company Highlights - AstraZeneca PLC (NASDAQ:AZN): - Price target raised to 16,000 GBp from 15,500 GBp by Guggenheim, maintaining a Buy rating after positive fiscal 2025 results [8]. - The FDA has accepted a supplemental Biologics License Application for Enhertu, with a Priority Review status for treating HER2-positive breast cancer [9][10]. - AstraZeneca focuses on developing and commercializing prescription medicines, including novel immuno-oncology treatments [11]. - Johnson & Johnson (NYSE:JNJ): - Citi increased the price target to $274 from $250 while maintaining a Buy rating, citing healthy sector fundamentals despite recent volatility [12]. - The company submitted a Type II variation application to the EMA for TECVAYLI® to treat relapsed/refractory multiple myeloma [13][14]. - Johnson & Johnson operates in healthcare, with segments in Innovative Medicine and MedTech, covering various therapeutic areas and medical devices [15].